PFIZER Inc has announced the US$51 million acquisition of a 15% stake in French gene therapy biotech company, along with an exclusive option to acquire the rest of the business.
The move will see Pfizer and Vivet collaborate on the development of VTX-801, a treatment for genetic disorder Wilson disease.
The above article was sent to subscribers in Pharmacy Daily's issue from 25 Mar 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 25 Mar 19
